The 12th International Plasma Product Biotechnology Meeting has ended.
Thanks to all presenters, session chairs and attendees for making the event very successful.
A special thanks to Dr. Kostiantyn Yefymenko, CEO of Biopharma Plasma in Ukraine for delivering the focus lecture, Pierre Delfante for giving patients perspectives and Dr. Dorothy Scott, from FDA (Chief of the Plasma Derivatives Branch) for representing regulatory bodies.
Stay tuned to receive updates on shared presentations and other information from this and future meetings.
The Plasma Product Biotechnology Conference Series has established a reputation as the key international forum for the presentation and discussion of topics relevant to the plasma manufacturing industry.
Session at the 2022 meeting were
- Advancing plasma therapeutics from early research to clinical trials
(Chairs: Sami Chtourou, K2C-BIOPHARM, Karl McCann, CSL Behring)
- Novel technologies and solutions for plasma fractionation
(Chair: Merche Faro, Grifols)
- Plasma 4.0 – digital transformation of the plasma business and manufacturing
(Chair: Barbara Kalina, CSL Behring)
- Safety, Quality and Regulatory aspects of plasma fractionation
(Chair: Beatrice Biebuyck, Takeda)
- Future perspectives on the plasma business and market
(Chair: Erik Youssef, Cytiva)
This is the event for you if you work in or have an interest in plasma manufacturing, through your work in a research institute, a government agency, a manufacturer, a supply company or consultancy, and seeking to update your knowledge of the industry, or to learn, explore or disseminate new ideas and information.
From the organizing committee, we would also like to thank Cytiva, CSL Behring, Takeda for their continued support Plasma Product Biotechnology Conference Series.